Yin chen

Yin Chen (Artemisiae Scopariae Herba)

1. Identity: Botanical Name, Natural Source, and Common Forms

Yin Chen, known in pharmacological literature as Artemisiae Scopariae Herba (ASH), is the dried aerial part of either Artemisia scoparia Waldst. et Kit. (called Bin Hao in Chinese) or Artemisia capillaris Thunb. (called Yin Chen Hao in Chinese). Also known as Yin Chen, Capillary Wormwood, or Oriental Wormwood, the plant belongs to the family Asteraceae. The two accepted species — A. capillaris and A. scoparia — are both recognized interchangeably as the pharmacopoeial source of Yin Chen in Chinese medicine, though they differ in their chemical profiles.

While A. capillaris is the main species used in medicinal formulations, A. scoparia contains higher levels of the essential active compound scoparone, whereas chlorogenic acid is more abundant in A. capillaris.

ASH is primarily distributed in the provinces of Shandong, Shanxi, Anhui, and Hebei in China and is widespread across Eurasia from central Europe to Japan, including India, North Korea, Mongolia, Russia, and Poland.

According to the Chinese Pharmacopoeia, ASH is harvested either when the spring seedlings are 6–10 cm high or when flowers are blooming in the autumn, referred to respectively as "Mian Yin Chen" and "Yin Chen Hao." Old stems and impurities are removed and the whole plants are dried in the sunlight. A distinction is made between ASH from small spring seedlings (Mian Yin Chen) and that from flowering plants in late summer/autumn (Yin Chen Hao), with each preferred for treating distinct sets of ailments.

Common Dosage Forms and Preparations

• Decoction (Tang): In classical prescriptions, Yin Chen Hao is decocted first — boiled alone in water, reducing the liquid by half, then the remaining herbs are added — to ensure full extraction of its active components.
• Classical formula decoctions: There are more than 200 kinds of traditional Chinese medicine prescriptions containing Yin Chen, such as Yin Chen Hao Tang, Yin Chen Wu Ling San, and Yin Chen Si Ni Tang.
• Oral liquid preparations: Modern Chinese clinical medicine frequently uses Yin Chen as the base formula for treating various hepatobiliary conditions, and derivative products such as Yinzhihuang oral liquid combine it with other herbs.
• Standardized granules and powders: The herb is also available commercially as cut dried herb, extract powder, and granules for decoction or direct consumption.
• Kampo preparation (Inchin-ko-to / TJ-135): In Japan, Yin Chen is central to the formula Inchin-ko-to (also designated TJ-135), which is known to inhibit hepatocyte apoptosis and promote the secretion and excretion of bile.

2. Traditional and Historical Use

Origins and Early Documentation

As a widely used herbal medicine, ASH is first recorded approximately 2,000 years ago in Shen Nong Ben Cao Jing (Divine Farmer's Materia Medica), the earliest pharmacological monograph of TCM. Yin Chen Hao was specifically documented in this canon for treating hepatic diseases.

It is also documented in the Compendium of Materia Medica (Ben Cao Gang Mu), compiled by Li Shizhen during the Ming Dynasty. Yin Chen's clinical applications are additionally recorded in Shang Han Lun, Jin Kui Yao Lue, Qian Jin Fang, and Ben Cao Gang Mu, primarily for its use in treating "Damp-Heat style" jaundice, hepatitis, heatstroke, and allergic inflammatory dermatitis.

Traditional TCM Characterization and Uses

Yin Chen Hao is considered a bitter and cooling herb, clearing "damp heat" from the liver and gall ducts and relieving fevers. In TCM theory, its primary action is on the liver and gallbladder, and it is classified by its taste (bitter, slightly acrid) and its thermal property (cool). The original uses of Artemisia capillaris in traditional Chinese medicine included the treatment of pyrexia (fever), jaundice, and dysuria.

In traditional Chinese medicine, Artemisia capillaris is commonly used to clear damp heat from the liver and gall ducts, and to treat jaundice and hepatitis.

The classical prescription Yin Chen Hao Tang — containing Yin Chen, Gardenia fruit (Zhi Zi), and Rhubarb (Da Huang) — is among the most historically significant TCM formulas for jaundice. Yinchenhao decoction (YCHD) is a classical TCM formula that has been widely used in the treatment of liver fibrosis caused by chronic hepatitis B and jaundice for more than 1,800 years. Yin Chen Hao is used in the largest dose within this formula. It is bitter, slightly pungent, and cool in nature, entering the Spleen, Stomach, Liver, and Gallbladder channels, and is described as the single most important herb in the entire TCM pharmacopoeia for treating jaundice.

Use Outside of China

In Japan, the formula Yin Chen Hao Tang is known as Inchin-ko-to and has been a subject of extensive pharmacological research since the 20th century. The herb and its classical formulas have also historically been used in Korea, where both A. capillaris and related Artemisia species have been used as hepatotherapeutic medicines.

3. Key Constituents and Active Compounds

Major Phytochemical Classes

Chemical constituents of Yin Chen include chlorogenic acid, salicylic acid, azelaic acid, pyrogallol tannins, oxalic acid, capillarisin, beta-elemene, beta-caryophyllene, alpha-humulene, essential oils, chromones, flavonoids, phenylalkynes, coumarins, benzoids, lignans, and scoparone.

Principal Bioactive Compounds

Scoparone (6,7-dimethoxycoumarin; 6,7-dimethylesculetin)

Scoparone, a widely recognised polymethoxylated coumarin, is considered the primary and significant active component of A. capillaris. The choleretic effect of scoparone is indirectly potentiated by cytochrome P450 1A2 via the bile salt export pump promoter. Scoparone is considered a potential hepatoprotective candidate for hepatitis therapy based on published evidence. Scoparone also has anti-atherogenic effects including the inhibition of vascular smooth muscle cell proliferation and migration, inhibition of platelet aggregation, and the attenuation of atherosclerotic plaque formation and dyslipidemia in hyperlipidemic diabetic rabbits. One study found that scoparone decreased peroxisome proliferator-activated receptor gamma (PPARγ) activity, expression of PPARγ target genes, and lipid accumulation in differentiating 3T3-L1 adipocytes.

Capillarisin

Capillarisin, a flavonoid constituent of Yin Chen, has potent hepatoprotective activity in vivo. In vitro, IFN-γ production is significantly suppressed by capillarisin in concanavalin A-stimulated splenocyte cultures, and nitrite release from IFN-γ-stimulated macrophages is also decreased. Capillarisin is derived naturally from chromone and has antioxidant, anti-inflammatory, and potential antitumor properties.

Scopoletin

Scopoletin isolated from A. capillaris contributes to bile secretion similarly to scoparone but has no effect on bile acid and cholesterol secretion.

Chlorogenic Acid

Chlorogenic acid (CGA), also named 3-O-Caffeoylquinic acid, is the ester of caffeic acid and quinic acid and is one of the most abundant and bioavailable dietary phenolic acids. It is one of the most plentiful phenolic compounds in A. capillaris and contributes to antioxidant, anti-inflammatory, and antiviral properties.

Capillin and Isochlorogenic Acid

Bioactive compounds include scoparone, scopoletin, capillarisin, capillin, chlorogenic acid, and isochlorogenic acid, which induce pharmacological effects of A. capillaris in a synergistic manner.

Effect of Harvest Timing on Phytochemical Profile

The harvested time and region of the plant also affect the chemical compositions of bioactive compounds. Both capillarisin and scoparone content reach peak levels in the leaf of A. capillaris at the end of July; however, the maximal level of capillarisin and scoparone is detected in the capitulum in early August and early September, respectively. The appropriate time to harvest A. capillaris is an important consideration that affects pharmacological actions, including possible toxicity from scoparone. The therapeutic benefits of A. capillaris are influenced by various parts of the plant and harvest time and should be balanced based on the contents of bioactive components.

4. Established Mechanisms of Action

Choleretic and Hepatobiliary Mechanisms

Modern clinical pharmacological studies have shown that Yin Chen contains a variety of choleretic ingredients, which can enhance gallbladder contraction, strengthen hepatocyte function, promote its regeneration, increase the secretion and excretion of bile acids, phospholipids and cholesterol in the liver, thereby promoting bile secretion and increasing the bilirubin and bile acid excretion. 6,7-Dimethoxycoumarin (scoparone), capillarisin, and germacrene D in volatile oil can promote bile secretion and excretion, increase the excretion of cholesterol bilirubin in bile, significantly reduce transaminases, and promote hepatocyte regeneration to reduce inflammation of hepatocytes and prevent hepatocyte necrosis.

Antioxidant Mechanisms

A. capillaris has been shown to significantly reduce the malondialdehyde (MDA) content in the liver of rats with bile duct ligation, and 50 and 100 mg/kg of its water extract notably decreased serum levels of MDA in alcohol-pyrazole-fed rats. A. capillaris was also found to restore significantly reduced levels of antioxidant enzymes including superoxide dismutase (SOD), glutathione (GSH), GSH-peroxidase, GSH-reductase, and catalases under conditions of oxidative stress in in vivo rat models.

Anti-Inflammatory Mechanisms

It has been reported that capillarisin (CPS) exposure effectively decreased the protein and mRNA expression of iNOS and COX-2, inhibited the production of NO and PGE2 without cytotoxic effects, and dose-dependently suppressed the secretion of TNF-α, IL-6, and IL-1β in RAW 264.7 cells through suppressing the activation of ERK, JNK, and NF-κB. Another study further demonstrated that CPS inhibited the phosphorylation of inhibitory kappa kinase (IKK) and IκB-α degradation, further blocked NF-κB p65 and p50 nuclear translocation, with these effects dependent on the inhibition of MyD88 and TIRAP inflammatory signaling-mediated Akt and MAPK pathways.

Pharmacokinetics of Key Compounds

The pharmacokinetics of the main bioactive compounds in A. capillaris show that they can achieve a maximum concentration within 1 hour, but only chlorogenic acid has a relatively long half-life. All compounds could reach the corresponding Cmax within an hour and diminished to half-concentration within 5 hours, except for chlorogenic acids, which could last more than a month.

The choleretic, anti-inflammatory, and antioxidant effects of A. capillaris are mainly attributed to scoparone, scopoletin, capillarisin, capillin, and chlorogenic acids, while antidiabetic, antisteatotic, and antitumor effects are principally derived from scopoletin, capillarisin, capillin, and chlorogenic acids.

5. Scientific Evidence by Area of Use

5.1 Liver Disease and Cholestasis

Artemisiae Scopariae Herba (ASH, or Yin Chen) is the most commonly used TCM herbal for the treatment of chronic liver diseases, especially cholestatic liver diseases.

Clinical (human) evidence — Cholestasis: Emerging clinical and experimental evidence has demonstrated that Yinchenhao decoction (YCHD) had promising therapeutic effects on cholestasis and was more effective than conventional therapies. A meta-analysis summarized 15 randomized controlled trials (RCTs) including 1,405 cases ranging from 2000 to 2014 and reported that YCHD efficiently improved long-term cholestasis and also potentiated the clinical efficiency of other anti-cholestasis medications.

Limitation: The RCTs included in this meta-analysis were conducted primarily in China, many use Yin Chen in multi-herb formulas rather than as an isolated single agent, and methodological quality is variable. The evidence base is therefore considered preliminary-to-moderate in strength, with better-designed trials needed.

Animal and in vitro evidence — Hepatoprotection: The antioxidant potential of A. capillaris extends to liver fibrosis and hepatoprotection, as demonstrated by measuring hydroxyproline (a marker of collagen synthesis) and liver function enzymes including AST and ALT in preclinical models.

Animal evidence — Hepatic steatosis (fatty liver): A. capillaris has been recognized as a candidate for hepatoprotective, hypoglycemic, hypolipidemic, anti-obesity, and anti-inflammatory therapeutic effectiveness. One study evaluated the anti-apoptotic activity of a 30% ethanol extract of AC (100 μg/ml) on free fatty acids-induced HepG2 cellular steatosis and lipoapoptosis. AC extract significantly improved the FFA-induced steatosis without cytotoxicity, and apoptosis-related proteins including Caspase-3, Caspase-9, Bax, and Bcl-2 were modulated beneficially in HepG2 cells after AC treatment. These findings are preclinical and have not yet been replicated in clinical trials.

5.2 Jaundice and Hyperbilirubinemia

Yin Chen Hao Tang was the foundational classical formula for treating jaundice within TCM. Clinical studies have shown that Yin-chen Wu-ling powder (YWP) can be used for the treatment of intrahepatic cholestasis of pregnancy, severe jaundice hepatitis, and acute jaundice hepatitis A. These are, however, primarily small-scale Chinese clinical reports; large, rigorously blinded controlled trials isolating Yin Chen as a single intervention are lacking. Yinchenhao Decoction (YCHD) is not recommended for treating neonatal jaundice due to concerns about its component herbs in neonates.

5.3 Viral Hepatitis (HBV)

Numerous studies have reported the antisteatotic, antioxidant, anti-inflammatory, choleretic, antiviral, antifibrotic, and antitumor activities of A. capillaris, supporting its therapeutic potential in liver diseases such as chronic hepatitis B virus (HBV) infection, cirrhosis, and hepatocellular carcinoma.

Studies have shown that combined therapy of TCM and conventional antiviral drugs has better efficacy than conventional antivirals alone in treating chronic hepatitis B. YinQiSanHuang-antiviral decoction (YQSH), a TCM compound preparation that includes Yin Chen, has shown an effect on anti-hepatitis B virus activity and on slowing the progression of hepatitis B-related liver diseases, and a randomized, double-blind, placebo-controlled trial was designed to evaluate its efficacy and safety in combination with entecavir. Clinical evidence for Yin Chen as an isolated antiviral agent against HBV in humans remains limited; most existing data involve multi-herb formulas in combination with standard antiviral therapy.

5.4 Liver Fibrosis and Cirrhosis

Animal evidence: The anti-hepatofibrotic effects of water extract of A. capillaris (AC) and Artemisia iwayomogi (AI), both used for hepatotherapeutic medicine in Korea, were comparatively analyzed using a carbon tetrachloride (CCl4)-induced liver fibrosis rat model. Results showed that AI exerts greater hepatoprotective and antifibrotic effects compared to AC, via enhancing antioxidant capacity and downregulating fibrogenic cytokines.

Clinical evidence (indirect): A study demonstrated that long-term TCM use may attenuate liver cirrhosis risk in patients with chronic hepatitis B; TCM users had a significantly lower liver cirrhosis risk than TCM non-users (adjusted HR = 0.416, 95% CI, 0.231–0.749), and histological evaluation revealed improved fibrosis in 45.0% of TCM users and 11.1% of TCM non-users. Yin Chen is a constituent of many such formulas, but its individual contribution cannot be isolated from these data.

5.5 Hepatocellular Carcinoma (HCC)

Evidence is at the preclinical (in vitro and animal) stage. An ethanol fraction (LAC117) from dried leaves of Artemisia capillaris strongly suppressed the growth and proliferation of human HCC cell lines (HepG2 and Huh7). Major constituents of AC such as capillin and scoparone exhibit anti-cancer effects in breast, prostate, lung, and liver cancers. No human clinical trials specifically evaluating Yin Chen for HCC prevention or treatment have been identified in current literature.

5.6 Metabolic Syndrome, Dyslipidemia, and Obesity

Evidence in this domain is principally from animal and cell-based studies. Artemisia capillaris extracts were used to treat high-fat diet rats, leading to decreased body weight and reduced levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and total cholesterol, with effects mediated by the downregulation of fatty acid synthase genes.

In addition to HBeAg inhibition and lowering of AST and ALT, A. capillaris activity includes lowering of triglycerides (TG), total cholesterol (TC), and LDL, and inhibition of α-glucosidase. Published studies have attributed these effects to verified bioactive compounds such as scoparone, scopoletin, capillarisin, capillin, and chlorogenic acids.

The ongoing global epidemics of obesity and metabolic disease require novel therapeutic approaches. While the mechanisms involved in A. scoparia's (SCOPA's) effects on metabolic, anti-inflammatory, and oxidative stress pathways are not fully characterized, current data support further investigation of this plant and its bioactives as potential therapeutic agents in obesity-related metabolic dysfunction. Human clinical trial data on Yin Chen for metabolic syndrome specifically are not yet established.

5.7 Antidiabetic Properties

Preclinical evidence suggests A. capillaris extracts may have antidiabetic effects, including α-glucosidase inhibition (relevant to post-prandial glucose management) and improvement of glucose tolerance in animal models. In cultured rat mesangial cells, high glucose-induced production of extracellular matrix proteins was reduced with scoparone treatment, a finding with potential implications for renal diabetic complications. As with metabolic syndrome, no human clinical trials specifically for glycemic outcomes using Yin Chen alone have been confirmed in available peer-reviewed literature.

5.8 Psoriasis and Dermatological Conditions

The pharmaceutical effects of A. capillaris are reported to contribute to the treatment of metabolic syndrome, psoriasis, and enterovirus in the clinic. However, the clinical evidence base for psoriasis specifically is limited; most reporting refers to traditional use and small clinical series in China rather than controlled trials. Historical texts document Yin Chen's clinical applications in the treatment of allergic inflammatory dermatitis.

5.9 Cardiovascular Effects (Preclinical)

Evidence shows that scoparone can mitigate cardiac ischemia/reperfusion injury in both in vitro and in vivo settings. Scoparone also has anti-atherogenic effects including inhibition of vascular smooth muscle cell proliferation and migration, inhibition of platelet aggregation, and attenuation of atherosclerotic plaque formation and dyslipidemia in hyperlipidemic diabetic rabbits. These findings are entirely preclinical; no human cardiovascular clinical trials for Yin Chen or scoparone have been identified in current sources.

5.10 Antimicrobial and Antiviral Properties

Yin Chen contains chemicals that stimulate bile flow and protect the liver. These chemicals might also kill cancer cells and viruses. The oils in yin chen might kill fungus and bacteria. These effects remain largely at the in vitro evidence stage. No well-controlled human clinical trials have established clinical antimicrobial or antiviral efficacy of Yin Chen as a standalone agent.

6. Body Systems and Health Areas Associated with Yin Chen

• Hepatobiliary system: Primary traditional and modern research focus; choleretic, hepatoprotective, anti-cholestatic, anti-fibrotic, and antisteatotic.
• Gastrointestinal system: Promotes bile flow, supports digestion, and influences gut motility via formula components.
• Metabolic system: Antisteatotic, antidiabetic (α-glucosidase inhibition), lipid-lowering effects documented in preclinical models.
• Immune system: Anti-inflammatory actions via NF-κB, MAPK, and cytokine pathways; immunomodulatory effects on T helper cells.
• Cardiovascular system: Anti-atherogenic and cardioprotective effects documented preclinically for scoparone.
• Integumentary system: Historical use in jaundice-related skin yellowing and allergic inflammatory dermatitis; psoriasis reported in clinical use.
• Oncological (preclinical): Anti-proliferative and pro-apoptotic effects in hepatocellular carcinoma and other cancer cell lines.

7. Dosage Forms and Dosages Reported in Studies

Dosage information for Yin Chen varies considerably by preparation form, formula context, and clinical application. The following reflect only figures reported in cited sources:

• Classical decoction (Yin Chen Hao Tang): The prepared decoction is divided into three portions and taken warm, three times daily (approximately 200 mL per dose). Yin Chen Hao is used in the largest dose, being triple that of Da Huang in the original prescription.
• Animal study dose (water extract, oral): In one murine study, orally administered Artemisia capillaris extract was given at 500, 1,000, or 2,000 mg per 10 mL per kg body weight, showing a decrease in serum transaminase activities and IFN-γ concentration in vivo.
• Animal study dose (water extract, antioxidant): 50 and 100 mg/kg of the water extract of A. capillaris notably decreased serum levels of MDA in alcohol-pyrazole-fed rats.
• In vitro cell study dose: A concentration of 100 μg/mL of a 30% ethanol extract of AC was evaluated on FFA-induced HepG2 cellular steatosis and lipoapoptosis.
• Scoparone (animal study): Scoparone at 60 mg/kg daily was evaluated for its ability to alleviate angiotensin II infusion-induced effects.
• Safety threshold (human, oral): High doses of 15 grams or more are considered possibly unsafe and can cause numbness, tremors, irregular heartbeat, and fainting.

Regarding use of the A. capillaris herb by health professionals to treat various diseases, the dosing schedule of this herb should be carefully considered to maximize therapeutic outcomes while lessening possible side effects.

8. Safety Considerations and Interactions

General Oral Safety

When taken by mouth, Yin Chen is possibly safe. It can cause nausea, bloating, and dizziness. High doses of 15 grams or more are possibly unsafe and can cause numbness, tremors, irregular heartbeat, and fainting.

Dermal Sensitization

Skin contact with some members of the Artemisia genus can cause dermatitis or other allergic reactions in some people.

Harvest Timing and Toxicity Risk

The appropriate time to harvest A. capillaris is an important consideration that affects pharmacological actions, including possible toxicity from scoparone. Over- or under-extraction due to incorrect harvest timing may alter the ratio of bioactive compounds and affect both efficacy and safety.

Pharmacokinetic Drug Interaction Signals

An herbal formula containing A. capillaris was found to be disproportional to its administering dose in the area under the curve (AUC) by monitoring its bioactive components, indicating pharmacokinetic saturation leading to excessive dosage or potential interaction with other drugs. The pharmacokinetic investigation of the A. capillaris-combined herbal formula appeared to interact with spironolactone, including the urinary sodium-to-potassium ratio.

A lack of information on the therapeutic window and pharmacodynamics that guide pharmacokinetics makes the efficacy and safety of herbal medicine questionable in some clinical contexts.

Neonatal Jaundice Contraindication

Yinchenhao Decoction (YCHD) is not recommended to be prescribed to treat neonatal jaundice. According to modern pharmacological and toxicological studies, it is well accepted that Rheum officinale (Da Huang/Rhubarb) and its anthraquinone derivatives in the YCHD formula contribute to the potential adverse effects of YCHD. This concern applies specifically to multi-herb formulations containing Rhubarb, not to Yin Chen in isolation.

Pregnancy

Self-administration during pregnancy is not recommended. Pregnant women experiencing jaundice should seek professional guidance before using formulas containing Yin Chen.

Species Misidentification Risk

Because the genus Artemisia contains numerous species — some with significantly different safety profiles — accurate botanical identification of the source species is essential. Artemisia absinthium (wormwood) and Artemisia annua are related but distinct species with different constituents, and products labeled simply as "wormwood" may not correspond to A. capillaris or A. scoparia.

References

• Wu S, et al. "The Pharmacological Effects and Pharmacokinetics of Active Compounds of Artemisia capillaris." Biomedicines. 2021;9(10):1412. PMC8533588.
• Cai Y, et al. "Recent progress in the study of Artemisiae Scopariae Herba (Yin Chen), a promising medicinal herb for liver diseases." Biomedicine & Pharmacotherapy. 2020;130:110513. ScienceDirect.
• Leu YL, et al. "Recent Studies and Progression of Yin Chen Hao (茵陳蒿 Yīn Chén Hāo), a Long-term Used Traditional Chinese Medicine." PMC3924980. Evid Based Complement Alternat Med. 2014.
• Yoon YD, et al. "A Survey of Therapeutic Effects of Artemisia capillaris in Liver Diseases." PubMed. 2015.
• Park SA, et al. "A Survey of Therapeutic Effects of Artemisia capillaris in Liver Diseases." PMC4558445.
• Kim YJ, et al. "Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma." PMC5941330. BMC Complement Altern Med. 2018.
• Kim JK, et al. "Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells." PMC4223594. BMC Complement Altern Med. 2014.
• Wu et al. "Insight into the metabolic mechanism of scoparone on biomarkers for inhibiting Yanghuang syndrome." PMC5116618. Sci Rep. 2016.
• Chen J, et al. "Yinchenhao decoction in the treatment of cholestasis: A systematic review and meta-analysis." J Ethnopharmacol. 2015;170:40–50. ScienceDirect.
• Boudreau A, et al. "Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use." Front Endocrinol. 2021;12:727061.
• Liu X, et al. "Serum metabolomics strategy for understanding the therapeutic effects of Yin-Chen-Hao-Tang against Yanghuang syndrome." PMC9078382. Front Pharmacol. 2022.
• Wu QJ, et al. "Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial." Trials. 2020;21:476. PMC7275558.
• YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial. PMC8515328. Trials. 2021.
• Cai FF, et al. "Yinchenhao decoction suppresses rat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis." Biomed Pharmacother. 2019;120:109480. ScienceDirect.
• WebMD Natural Medicines. "Yin Chen: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews."
• Exploring the Therapeutic Potential of Artemisia and Salvia Genera in Cancer, Diabetes, and Cardiovascular Diseases: A Short Review of Clinical Evidence. PMC11818717. Pharmaceuticals. 2025.
• A Comprehensive Multiomics Approach Illuminates the Biosynthetic Mechanism of Scoparone in Artemisia capillaris. PMC12854908.
• Me and Qi. "Yin Chen Hao Tang (茵陈蒿汤) — TCM Formula." MeandQi.com.